President Biden’s Proposal To Expand Medicare Price Controls A Sign Of Things To Come

Even though it is unlikely that the policies will succeed in the currently divided Congress, the proposal reinforces industry’s concerns that once a foundation for Medicare price negotiation is established, policymakers will try to build on it.

Budget Proposal Is Messaging Document That Highlights Democrats' Goals • Source: Shutterstock

President Biden is confirming the biopharma industry’s worst fears with his proposal to expand the Medicare price negotiation program established by the Inflation Reduction Act to drugs even earlier in their lifecycle. The plan is included in the president’s federal budget proposal for 2024, to be formally unveiled on 9 March.

The policies are not likely to advance in Congress as long as Republicans control the House. But the fact that...

More from Market Access

More from Pink Sheet

Room For Improvement? EU Industry Prepares Feedback For SPC Manufacturing Waiver Review

 
• By 

As the European Commission prepares a formal evaluation of the SPC manufacturing waiver, the generics and biosimilars industry is getting ready to provide detailed feedback on what works – and what doesn’t. At Medicines for Europe’s legal affairs conference, delegates heard the latest updates.

Report Shows Extent Of AI Use In EU Medicines Regulation During 2024

 

The AI observatory, created by the European medicines regulatory network to track the evolving use of artificial intelligence in medicines development and regulation, has issued its first annual report.

Prasad Cites Unproven Theory Defending His COVID-19 Vaccine Decisions

 

In defending his decision to overrule agency staff on three recent COVID-19 vaccine applications, the CBER director questioned the original timing of Pfizer’s COVID-19 vaccine authorization, reviving a long-held, but unproven grievance of President Trump.